- Why does impaired cellular immunity increase the risk for Pneumocystis jiroveci Pneumonia (PJP)? How do acquired humoral immune deficiencies, such as the use of rituximab, increase the risk for PJP?
- At what dose of chronic steroids use should patients be given prophylaxis for PJP?
The patient is a 35-year-old man with a history of psoriatic arthritis and complex regional pain syndrome on prednisone, methotrexate and abatacept who presented with two weeks of dyspnea on exertion and cough. Three months prior to admission, the patient increased his dose of prednisone (from 10mg to 20mg daily) to better control his psoriatic arthritis.
Progressive dyspnea on exertion appeared two weeks prior to presentation and a nonproductive cough developed one week prior to presentation. The patient also reported night sweats during this time but otherwise denied fevers, chills, chest pain or palpitations, leg swelling or wheezing. He had no recent travel history, sick contacts or occupational exposures.
On arrival, the patient was afebrile with a heart rate of 114 beats per minute, a respiratory rate of 24 breaths per minute and an oxygen saturation of 92% on ambient air. The physical exam was notable for fine crackles and bronchial breath sounds over the right mid-lower lung field. Initial labs revealed white blood cell count of 21.9 K/uL with 80% neutrophils but was otherwise unremarkable. A rapid HIV test was negative. Chest XR demonstrated right middle and lower lobe consolidations and left basilar hazy opacities consistent with multifocal pneumonia. He was started on antibiotics for community acquired pneumonia and admitted to the hospital.
The patient’s dyspnea continued to worsen over the first two hospital days despite antibiotic therapy. On hospital day 2 beta-d-glucan was noted to be positive (> 500 pg/mL). Later that day his respiratory status decompensated necessitating ICU transfer and intubation. Bronchial lavage identified Pneumocystis jiroveci on routine and PAS stain. He was treated with IV TMP-SMX and prednisone. He recovered and was discharged to inpatient pulmonary rehabilitation.
This case highlights a young, chronically ill, HIV-negative patient on chronic immunosuppressive medications who presented with worsening constitutional symptoms and dyspnea and was found to have PJP. While this case raises many learning points, we narrowed our focus to two specific questions. First we will review specific types of immunodeficiency, namely cellular versus humoral, and discuss implications on the risk for PCP. The second question will address the evidence for giving antibiotics as prophylaxis for PCP pneumonia in patients who are on chronic steroids.
The pneumocystis pathogen-host interaction is well-described. It used to be thought that colonization was ubiquitous and disease only occurred once immunodeficiency developed. However, a number of laboratory, clinical and epidemiologic studies challenged this. For example, pneumocystis strains vary within cities and infected patients’ strains tend to be more similar to their current location rather than their birth location.
Mouse models to study pneumocystis infection often involve T-cell deficient animals which causes severe combined immunodeficiency (SCID). In these mice, PCP infection develops quickly and spontaneously. These mice have intact neutrophils and macrophages, yet cannot clear the organism. When CD4+ T cells are reconstituted the mice are able to clear the infection. CD4+ cells also generate interferon-g and lymphotactin, which function as potent chemokines. CD4+ activated alveolar macrophages produce large amounts of tumor necrosis factor (TNF), which further recruits inflammatory cells to participate in pathogen clearance.
An important feature of the case presented was the ongoing treatment with abatacept. This biologic agent typically used for rheumatoid arthritis is a monoclonal antibody against CD80 and CD86 on T cells. These cell-surface proteins provide the necessary co-signaling for T cell activation and proliferation. The medication effectively induces a mild form of SCID. In a similar case report of PCP in a patient being treated with abatacept, there was co-treatment with methotrexate. Although considered safe, there is an increased risk of the same invasive fungal infections with abatacept treatment as SCID patients often experience.
Independent of the inflammatory response that it mediates, the pneumocystis infection is fairly benign. The pneumocystis-infected SCID mice described above had preserved oxygenation and lung function until later stages of the disease. It wasn’t until splenic CD4+ T cells were reintroduced that these mice experienced impaired lung function and tissue oxygenation as a result of the dysregulated response. An analogous phenomena occurs when HIV-positive patients initiate anti-retroviral therapy during PCP treatment causing the immune reconstitution inflammatory syndrome.
This observation explains some of the clinical differences in pneumocystis infections in HIV-infected versus uninfected patients. Those with HIV develop pneumonia that is characterized by indolent progression of the disease. Bronchoalveolar lavage (BAL) in these patients demonstrates large numbers of organisms and few neutrophils (but abundant macrophages and CD8+ T cells). In the HIV-uninfected population, PCP is fulminant with greater morbidity and mortality. BAL analyses in HIV-uninfected patients demonstrate few organisms that evoke a robust neutrophilic response with alveolar inflammation and oxidative damage.
It also appears that the humoral immune response plays an important role in the pneumocystis infection response. There have been reports of spontaneous outbreaks of PCP in B-cell deficient mice with fully intact cellular immune systems. Subsequent studies have noted that clearance of pneumocystis is dependent on B cells but not on pneumocystis-specific antibodies. This suggests that B cells play a role in T cell activation in the clearance of pneumocystis, and explains the risk imposed on patients getting rituximab therapy. A Mayo Clinic review of PCP cases in patients exposed to rituximab demonstrated that while infection can occur during monotherapy it is much more common when used in combination with cytotoxic chemotherapy or high dose glucocorticoids.
In the HIV-positive population the risk of PCP below a CD4+ T cell count of 200 makes the threshold at which to initiate primary prophylaxis straightforward. No such level exists for HIV-uninfected patients at risk for PCP, and as new immunosuppressive medications become more widely available this population will continue to grow. One particularly challenging subset of at-risk HIV-uninfected patients are those on chronic glucocorticoids. The 2011 American Thoracic Society guidelines recommend consideration of PCP prophylaxis in patients taking chronic steroids if the dose is greater than or equal to 20mg of prednisone daily for one month, especially if there are concomitant T cell deficits, cytotoxic or anti-TNF agents. This dose and duration first appeared in the literature in the late 1980s to mid-1990s with the publication of several case series of HIV-uninfected patients diagnosed with PCP.,, Prolonged corticosteroid use with concomitant immunosuppressive disease or medication was the common thread throughout the vast majority of these patients. In these reports, one from Memorial Sloan Kettering Cancer Center (MSKCC) and two from the Mayo Clinic, the median daily dose was 20-80mg of prednisone daily for 9 weeks to 3 months. The recommendation of 20mg daily prednisone for 4 weeks appears to be the MSKCC prophylactic policy that is then referenced-forward.
Pneumocystis pneumonia is a life-threatening infection that was first recognized in the HIV-infected population. In the early days of the AIDS epidemic the prevalence of PCP in patients with low CD4+ T cell counts helped us understand the importance of cellular immunity in controlling the infection. The observed clinical differences between HIV-infected and HIV-uninfected patients with PCP clarified the role of a dysregulated immune response as the primary culprit in pulmonary damage due to pneumocystis.
Dr. Martin Fried is a chief resident, internal medicine, NYU Lutheran
Peer reviewed by Dr. Howard Leaf, infectious diseases, NYU Langone Health
Image courtesy of Wikimedia Commons
 Thomas, Charles F., and Andrew H. Limper. “Current insights into the biology and pathogenesis of Pneumocystis pneumonia.” Nature Reviews Microbiology 5.4 (2007): 298-308. http://www.nature.com/nrmicro/journal/v5/n4/abs/nrmicro1621.html?foxtrotcallback=true
 Morris, Alison, C. Ben Beard, and Laurence Huang. “Update on the epidemiology and transmission of Pneumocystis carinii.” Microbes and infection 4.1 (2002): 95-103.
 Roths, J. B., Marshall, J. D., Allen, R. D., Carlson, G. A. & Sidman, C. L. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. Natural history and pathobiology. Am. J. Pathol. 136, 1173–1186 (1990).
 Wright, T. W., Johnston, C. J., Harmsen, A. G. & Finkelstein, J. N. Chemokine gene expression during Pneumocystis carinii-driven pulmonary inflammation. Infect. Immun. 67, 3452–3460 (1999). https://www.ncbi.nlm.nih.gov/pubmed/10377126
 Ospina, Fabio E., et al. “Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with abatacept.” Case reports in rheumatology 2014 (2014). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182847/
 Ponce, Carolina A., et al. “Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population.” Clinical infectious diseases50.3 (2010): 347-353.
 Tasaka, Sadatomo, and Hitoshi Tokuda. “Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies.” Journal of Infection and Chemotherapy 18.6 (2012): 793-806. https://www.ncbi.nlm.nih.gov/pubmed/22864454
 Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000;118:704-11
 Limper, Andrew H., et al. “Pneumocystis carinii pneumonia: differences in lung parasite number and inflammation in patients with and without AIDS.”American review of respiratory disease 140.5 (1989): 1204-1209. https://www.ncbi.nlm.nih.gov/pubmed/2817582
 Marcotte, Harold, et al. “Pneumocystis carinii infection in transgenic B cell-deficient mice.” Journal of Infectious Diseases 173.4 (1996): 1034-1037.
 Lund, Frances E., et al. “Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P. carinii-specific antibody.” The Journal of Immunology 171.3 (2003): 1423-1430.
 Martin-Garrido, Isabel, et al. “Pneumocystis pneumonia in patients treated with rituximab.” CHEST Journal 144.1 (2013): 258-265. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694106/
 Stansell, John D., et al. “Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group.” American journal of respiratory and critical care medicine 155.1 (1997): 60-66.
 Limper, Andrew H., et al. “An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients.”American journal of respiratory and critical care medicine 183.1 (2011): 96-128. http://www.atsjournals.org/doi/abs/10.1164/rccm.2008-740ST
 Arend, Sandra M., Frank P. Kroon, and Jan W. van’t Wout. “Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993: an analysis of 78 cases.” Archives of internal medicine 155.22 (1995): 2436-2441.
 Sepkowitz, Kent A., et al. “Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital.” Jama 267.6 (1992): 832-837.
 Yale, Steven H., and Andrew H. Limper. “Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy.” Mayo Clinic Proceedings. Vol. 71. No. 1. Elsevier, 1996.
 Sepkowitz, Kent A., Arthur E. Brown, and Donald Armstrong. “Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: more patients, same risk.” Archives of internal medicine 155.11 (1995): 1125-1128. https://www.ncbi.nlm.nih.gov/pubmed/7763117